In addition: “SGLT2 inhibitors, unlike thiazolidinediones [a commonly used class of diabetes drugs], have a tendency to increase fluid excretion by a mechanism that depends on osmotic diuresis.

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

Teams of researchers are investigating empagliflozin and dapagliflozin in patients with autosomal dominant polycystic kidney disease (AD PKD).

The use of SGLT2 vs DPP4 inhibitors was linked to reduced cardiovascular and renal risks among patients with comorbid SLE and T2D.

But, "the mechanism of action is open to speculation," she said. SGLT2 inhibitors have diuretic and anti-inflammatory effects ...

"These findings reinforce the use of dapagliflozin, 10 mg, or other SGLT2 inhibitors when the therapeutic goal is to reduce ...

Phlorizin opened the way for a new promising class of antidiabetic agents. The main action of SGLT2 inhibitors is the induction of glucosuria and osmotic diuresis. Further features, benefits and ...

Merck and Pfizer are hoping to cover all bases if they get their latest SGLT2 inhibitor to market. There is a crowd of already-approved rivals, but the companies are doing their best to ensure ...

Other SGLT-2 inhibitors are similar in action ... [22] While the frequency and mechanism of this complication require more study, clinicians and patients need to appreciate the potential risk ...

If you continue to have this issue please contact customerservice@slackinc.com. Starting SGLT2 inhibitors led to a lower risk of eGFR decline or incident kidney failure. SGLT2 inhibitors were also ...